92 related articles for article (PubMed ID: 18779044)
1. Coinfection alters the playing field: herpesviruses induce acyclovir to inhibit HIV.
Stapleton JT; Balfour HH
Cell Host Microbe; 2008 Sep; 4(3):194-5. PubMed ID: 18779044
[TBL] [Abstract][Full Text] [Related]
2. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues.
Lisco A; Vanpouille C; Tchesnokov EP; Grivel JC; Biancotto A; Brichacek B; Elliott J; Fromentin E; Shattock R; Anton P; Gorelick R; Balzarini J; McGuigan C; Derudas M; Götte M; Schinazi RF; Margolis L
Cell Host Microbe; 2008 Sep; 4(3):260-270. PubMed ID: 18779052
[TBL] [Abstract][Full Text] [Related]
3. Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.
Derudas M; Vanpouille C; Carta D; Zicari S; Andrei G; Snoeck R; Brancale A; Margolis L; Balzarini J; McGuigan C
J Med Chem; 2017 Sep; 60(18):7876-7896. PubMed ID: 28829913
[TBL] [Abstract][Full Text] [Related]
4. Bipolar hypertrophic herpes: an unusual presentation of acyclovir-resistant herpes simplex type 2 in a HIV-infected patient.
Cury K; Valin N; Gozlan J; Jacquier I; Boutolleau D; Guegan S; Flejou JF; Girard PM
Sex Transm Dis; 2010 Feb; 37(2):126-8. PubMed ID: 19858782
[TBL] [Abstract][Full Text] [Related]
5. HSV therapy and HIV-1 reduction.
Martinez V; Caumes E
N Engl J Med; 2007 May; 356(22):2323; author reply 2324. PubMed ID: 17538093
[No Abstract] [Full Text] [Related]
6. Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs.
McMahon MA; Siliciano JD; Kohli RM; Siliciano RF
AIDS; 2010 Jan; 24(2):319-23. PubMed ID: 20009920
[TBL] [Abstract][Full Text] [Related]
7. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.
Schacker T; Zeh J; Hu H; Shaughnessy M; Corey L
J Infect Dis; 2002 Dec; 186(12):1718-25. PubMed ID: 12447756
[TBL] [Abstract][Full Text] [Related]
8. The emergence of acyclovir resistance in mucocutaneous herpes simplex viral infections: implications for clinical practice.
Grodesky MJ
Nurse Pract; 1997 Jun; 22(6):155-6. PubMed ID: 9211458
[No Abstract] [Full Text] [Related]
9. Decreased monocyte activation with daily acyclovir use in HIV-1/HSV-2 coinfected women.
Redd AD; Newell K; Patel EU; Nalugoda F; Ssebbowa P; Kalibbala S; Frank MA; Tobian AA; Gray RH; Quinn TC; Serwadda D; Reynolds SJ
Sex Transm Infect; 2015 Nov; 91(7):485-8. PubMed ID: 25904747
[TBL] [Abstract][Full Text] [Related]
10. Antivirals in the context of HIV disease.
Wood MJ
J Antimicrob Chemother; 1996 May; 37 Suppl B():97-112. PubMed ID: 8818833
[TBL] [Abstract][Full Text] [Related]
11. Phosphoramidate derivatives of acyclovir: synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro.
Zakirova NF; Shipitsyn AV; Jasko MV; Prokofjeva MM; Andronova VL; Galegov GA; Prassolov VS; Kochetkov SN
Bioorg Med Chem; 2012 Oct; 20(19):5802-9. PubMed ID: 22954898
[TBL] [Abstract][Full Text] [Related]
12. Atypical presentations of genital herpes simplex virus in HIV-1 and HIV-2 effectively treated by imiquimod.
McKendry A; Narayana S; Browne R
Int J STD AIDS; 2015 May; 26(6):441-3. PubMed ID: 24912536
[TBL] [Abstract][Full Text] [Related]
13. Aciclovir for dual infection with HIV and HSV.
Verjans GM; Boucher CA
Lancet Infect Dis; 2012 Jun; 12(6):424-5. PubMed ID: 22433278
[No Abstract] [Full Text] [Related]
14. Surgical excision for recurrent herpes simplex virus 2 (HSV-2) anogenital infection in a patient with human immunodeficiency virus (HIV).
Arinze F; Shaver A; Raffanti S
Infection; 2017 Oct; 45(5):705-707. PubMed ID: 28508238
[TBL] [Abstract][Full Text] [Related]
15. Consistent inhibition of HIV-1 replication in CD4+ T cells by acyclovir without detection of human herpesviruses.
McMahon MA; Parsons TL; Shen L; Siliciano JD; Siliciano RF
J Virol; 2011 May; 85(9):4618-22. PubMed ID: 21325417
[TBL] [Abstract][Full Text] [Related]
16. Self-collected genital swabs compared with cervicovaginal lavage for measuring HIV-1 and HSV-2 and the effect of acyclovir on viral shedding.
McNicholl JM; Leelawiwat W; Whitehead S; Hanson DL; Evans-Strickfaden T; Cheng CY; Chonwattana W; Mueanpai F; Kittinunvorakoon C; Markowitz L; Dunne EF
Int J STD AIDS; 2017 Mar; 28(4):372-379. PubMed ID: 27179350
[TBL] [Abstract][Full Text] [Related]
17. [The efficiency of combined therapy of herpes virus infection in HIV infected patients].
Papuashvili MN; Shchelkanov MIu
Vopr Virusol; 2004; 49(2):25-9. PubMed ID: 15106380
[TBL] [Abstract][Full Text] [Related]
18. Fulminant, acyclovir-resistant, herpes simplex virus type 2 hepatitis in an immunocompetent woman.
Czartoski T; Liu C; Koelle DM; Schmechel S; Kalus A; Wald A
J Clin Microbiol; 2006 Apr; 44(4):1584-6. PubMed ID: 16597901
[TBL] [Abstract][Full Text] [Related]
19. A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus.
Franchetti P; Abu Sheikha G; Cappellacci L; Marchetti S; Grifantini M; Balestra E; Perno C; Benatti U; Brandi G; Rossi L; Magnani M
Antiviral Res; 2000 Sep; 47(3):149-58. PubMed ID: 10974367
[TBL] [Abstract][Full Text] [Related]
20. How does herpes simplex virus type 2 influence human immunodeficiency virus infection and pathogenesis?
Wald A; Corey L
J Infect Dis; 2003 May; 187(10):1509-12. PubMed ID: 12721930
[No Abstract] [Full Text] [Related]
[Next] [New Search]
